Munich, Germany – December 4, 2024 – Thermosome, a drug development company focused on targeted tumor therapies, today announced its ongoing Phase I trial has progressed to dose level 3 (DL3) after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback